RT Journal Article
SR Electronic
T1 COVID-19 in 823 Transplant patients: A Systematic Scoping Review
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.18.21250025
DO 10.1101/2021.01.18.21250025
A1 Moataz Maher Emara
A1 Mahmoud Elsedeiq
A1 Mohamed Elmorshedi
A1 Hamed Neamatallah
A1 Mostafa Abdelkhalek
A1 Amr Yassen
A1 Ashraf Nabhan
YR 2021
UL http://medrxiv.org/content/early/2021/01/20/2021.01.18.21250025.abstract
AB Background Management of COVID-19 in transplant patients is a big challenge. Data on immunosuppression management, clinical picture, and outcomes are lacking.Objectives To summarize the current literature on COVID-19 in transplant patients especially the data regarding the immunosuppression protocols, clinical presentation, and outcomes.Search strategy A systematic search of MEDLINE, EBSCO, CENTRAL, CINAHL, LitCovid, Web of Science, and Scopus electronic databases. The references of the relevant studies were also searched. The search was last updated on June 3, 2020.Selection Criteria Primary reports of solid organ transplant patients who developed COVID-19. An overlap of cases in different reports was checked.Data collection and analysis A descriptive summary of immunosuppression therapy (before and after COVID-19), clinical presentation (symptoms, imaging, laboratory, and disease severity), management (oxygen therapy, antiviral, and antibacterial), major outcomes (Intensive care admission, invasive mechanical ventilation, acute kidney injury), and mortality.Main results We identified 74 studies reporting 823 cases of solid organ transplantation with COVID-19. Among 372 patients, 114 (30.6%) were mild COVID-19, 101 (27.2%) moderate, and 157 (42.2%) severe or critical.Major outcomes included intensive care unit admission, invasive ventilation, and acute kidney injury, which occurred in 121 (14.7%), 97 (11.8%), and 63 (7.7%) of patients, respectively. Mortality was reported in 160 (19.4%) patients. Missing individual data hindered making clinical correlations.Conclusion COVID-19 in solid organ transplant patients probably has a more disease severity, worse major outcomes (Intensive care admission, invasive ventilation, acute kidney injury), and higher mortality than in non-transplant patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThere is no external funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB approval is not relevant to this research.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be available on request.AKIAcute Kidney InjuryARDSAcute Respiratory Distress SyndromeCNICalcineurine inhibitorCRPC-reactive proteinCTComputed TomographyECMOExtracorporeal Membrane OxygenationICUIntensive Care UnitLDHLactate DehydrogenasemTORimammalian Target Organ of Rapamycin inhibitorMVMechanical VentilationMMFMycophenolate MofetilPRISMAPreferred Reporting Items for Systematic Review and Meta-Analysisrt-PCRreverse transcription – Polymerase Chain ReactionSARS-CoV-2severe acute respiratory syndrome – coronavirus-2